AbbVie has fallen 30% from YTD highs after fears about competition from biosimilars and a short call made by by Citron. But Citrons short calls have been hit and miss in this space and ABBV's licensing agreements should keep out Amgen and Mylan until after 2023. Yesterdays beat and raise provide further reasons to cheer. PE is 12x full year guidance
https://www.fool.com/investing/2018/07/27/2-reasons-the-market-frowned-after-abbvies-blowout.aspx
This post is not a recommendation to buy or sell any security or derivative. Stocks are not suitable for all investors. Please do your own research.
Submitted July 28, 2018 at 10:24AM by InterestingNews1 https://ift.tt/2Lw27wg
No comments:
Post a Comment